INDV

Indivior Pharmaceuticals Inc · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-26

Figures on this page computed 2026-11-08 12:32 UTC

Last close

36.28USD

Market data, 2026-11-02

Except where said otherwise: 10-K for 2025, filed 2026-02-26

21.6xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001628280-26-012237
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-26
The filing itself
396.9%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001628280-26-012237
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-10-29
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-10-29
The filing itself
16.9%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001628280-26-012237
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
The filing itself
-7.5%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001628280-26-012237
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001628280-26-012237
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-10-29
The filing itself
n/aDividend yield
The stored value is a zero that stands for missing data rather than a measurement, so we will not place it.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
- Computed from the filing for 2016

Safety is the furthest below its sector's middle: 0.44 against 0.53 on the market's range.

What it pays out: n/aThe stored value is a zero that stands for missing data rather than a measurement, so we will not place it.

All from 100

lens 2 of 9

Sales

128

2016-12-31 to 2025-12-31100 at the start128

Sales: 100.00 on 2016-12-31 to 127.88 on 2025-12-31, up 28%.

Profit

655

2016-12-31 to 2025-12-31100 at the start655

Profit: 100.00 on 2016-12-31 to 655.19 on 2025-12-31, up 555%.

Shares in issue

92.1

2022-12-31 to 2025-12-31100 at the start92.1

Shares in issue: 100.00 on 2022-12-31 to 92.09 on 2025-12-31, down 8%.

Sales is at 128, Profit is at 655, Shares in issue is at 92, against 100 in 2016.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-02-26

Sales, where the first year is 100128
Source
filed
Statement
income
Fiscal year
2025
Accession
0001628280-26-012237
Reported in
USD
The filing itself
Profit, where the first year is 100655
Source
filed
Statement
income
Fiscal year
2025
Accession
0001628280-26-012237
Reported in
USD
The filing itself
Shares in issue, where the first year is 10092
Source
filed
Statement
income
Fiscal year
2025
Accession
0001628280-26-012237
Reported in
USD
The filing itself